1. Broad dengue neutralization in mosquitoes expressing an engineered antibody
- Author
-
Chun-Hong Chen, Stephanie Gamez, James E. Crowe, Prasad N. Paradkar, Jean-Bernard Duchemin, Igor Antoshechkin, Shin-Wei Wang, Anna Buchman, Omar S. Akbari, Shin-Hang Lee, Ming Li, Melissa J. Klein, Section of Cell and Developmental Biology, University of California [San Diego] (UC San Diego), University of California-University of California, Division of Biology and Biological Engineering [Pasadena, USA] (BBE), California Institute of Technology (CALTECH), National Tsing Hua University [Hsinchu] (NTHU), National Mosquito-Borne Diseases Control Research Center [Taiwan], National Health Research Institutes [Taiwan] (NHRI), National Institute of Infectious Diseases and Vaccinology [Taiwan] (NHRI-IV), CSIRO Health and Biosecurity [Australia], Commonwealth Scientific and Industrial Research Organisation [Canberra] (CSIRO), Australian Centre for Disease Preparedness - Australian Animal Health Laboratory [Australia] (ACDP), Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], Tata Institute for Genetics and Society's [La Jolla] (TIGS), University of California-University of California-Tata Institute for Fundamental Research (TIFR)-Institute for Stem Cell Biology and Regenerative Medicine [Bengaluru, India], This work was supported in part by a Defense Advanced Research Project Agency (DARPA) Safe Genes Program Grant (HR0011-17-2- 0047) awarded to O.S.A. and a NIH Exploratory/Developmental Research Grant Award (1R21AI123937) awarded to O.S.A and CSIRO internal funding to P.N.P. The funders had no role in study design, data collection, analysis, the decision to publish, nor the preparation of the manuscript, and Suthar, Mehul
- Subjects
0106 biological sciences ,Serotype ,Male ,MESH: Broadly Neutralizing Antibodies / immunology ,MESH: Aedes / virology ,Dengue virus ,Pathology and Laboratory Medicine ,Antibodies, Viral ,Protein Engineering ,01 natural sciences ,Biochemistry ,Neutralization ,0302 clinical medicine ,Mosquito ,Dengue transmission ,MESH: Animals ,Vector (molecular biology) ,Biology (General) ,0303 health sciences ,Denv serotypes ,Philosophy ,030302 biochemistry & molecular biology ,Eukaryota ,virus diseases ,Limiting ,3. Good health ,MESH: Protein Engineering ,Blood ,Medical Microbiology ,MESH: Broadly Neutralizing Antibodies / genetics ,Viral Pathogens ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Engineering and Technology ,Antibody ,Infection ,QH301-705.5 ,Immunology ,Bioengineering ,Plasmid construction ,Monoclonal antibody ,Microbiology ,03 medical and health sciences ,Biodefense ,Genetics ,Humans ,Saliva ,Microbial Pathogens ,Molecular Biology ,MESH: Humans ,Flaviviruses ,Prevention ,Organisms ,Biology and Life Sciences ,Proteins ,Correction ,Dengue Virus ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Invertebrates ,Virology ,Insect Vectors ,Vector-Borne Diseases ,[SDV.BA.ZI]Life Sciences [q-bio]/Animal biology/Invertebrate Zoology ,010602 entomology ,Species Interactions ,Molecular biology techniques ,Genetic engineering ,Parasitology ,Immunologic diseases. Allergy ,MESH: Female ,Developmental Biology ,RNA viruses ,Life Cycles ,MESH: Antibodies, Viral / immunology ,Physiology ,viruses ,Disease Vectors ,medicine.disease_cause ,Mosquitoes ,Dengue fever ,Dengue ,Larvae ,Aedes ,Immune Physiology ,Medicine and Health Sciences ,Viral ,030212 general & internal medicine ,Immune System Proteins ,Transmission (medicine) ,Body Fluids ,Insects ,Infectious Diseases ,Viruses ,MESH: Antibodies, Viral / biosynthesis ,Female ,Anatomy ,Pathogens ,Research Article ,Biotechnology ,Arthropoda ,medicine.drug_class ,MESH: Antibodies, Viral / genetics ,MESH: Dengue Virus / immunology ,Aedes aegypti ,Biology ,DNA construction ,Antibodies ,Vaccine Related ,Rare Diseases ,parasitic diseases ,medicine ,Animals ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,030304 developmental biology ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,RC581-607 ,biology.organism_classification ,MESH: Single-Chain Antibodies / genetics ,MESH: Male ,Research and analysis methods ,Emerging Infectious Diseases ,Good Health and Well Being ,MESH: Aedes / genetics ,MESH: Broadly Neutralizing Antibodies / biosynthesis ,biology.protein ,Broadly Neutralizing Antibodies ,Single-Chain Antibodies - Abstract
With dengue virus (DENV) becoming endemic in tropical and subtropical regions worldwide, there is a pressing global demand for effective strategies to control the mosquitoes that spread this disease. Recent advances in genetic engineering technologies have made it possible to create mosquitoes with reduced vector competence, limiting their ability to acquire and transmit pathogens. Here we describe the development of Aedes aegypti mosquitoes synthetically engineered to impede vector competence to DENV. These mosquitoes express a gene encoding an engineered single-chain variable fragment derived from a broadly neutralizing DENV human monoclonal antibody and have significantly reduced viral infection, dissemination, and transmission rates for all four major antigenically distinct DENV serotypes. Importantly, this is the first engineered approach that targets all DENV serotypes, which is crucial for effective disease suppression. These results provide a compelling route for developing effective genetic-based DENV control strategies, which could be extended to curtail other arboviruses., Author summary With limited success of traditional vector control methods to curb dengue infections and more than half of the world’s population still at risk, there is a need for novel strategies to reduce its impact on public health. Recent advances in genetic technologies has allowed for precise modifications of mosquito genome to make them resistant to infections, thus breaking the transmission cycle. Here we generated engineered Ae. aegypti mosquitoes efficiently expressing a DENV-targeting single-chain variable fragment (scFv) derived from a previously characterized broadly neutralizing human antibody, which blocked infection and transmission in these mosquitoes. To our knowledge, this is the first example of an engineered transgene capable of rendering Ae. aegypti mosquitoes 100% refractory to all four serotypes of DENV. The engineered mosquitoes, in future, could easily be paired with a gene drive, capable of spreading the transgene throughout wild disease-transmitting mosquito populations and preventing further DENV transmission. Since a number of diverse and well-characterized antibodies exist against other arboviruses (eg chikungunya and Zika, this work also provides a proof-of-concept principle for developing similar genetic strategies for reducing the impact of these arboviruses.
- Published
- 2020